This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company.
Results show excellent early functional recovery in clinically complex patients with advanced prostate cancer ... Read More ...
Stockhead on MSN
ASX healthcare stocks advance new approaches to prostate cancer
ASX-listed healthcare companies are advancing new approaches to prostate cancer, spanning imaging, targeted therapies and ...
Nerve-sparing radical prostatectomy (NSRP) yields comparable oncologic outcomes to surgery that does not spare the neurovascular bundles in men with high-risk prostate cancer, investigators report. In ...
PERTH, Australia, Sept. 16, 2025 /PRNewswire/ -- Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") is pleased to announce its flagship nerve repair device, ...
Real-world, prospective data corroborate trial results showing functional declines after prostate cancer surgery, despite progress in nerve-sparing techniques. Active surveillance best preserves ...
Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed PERTH, Australia, Nov. 20, 2025 /PRNewswire/ -- Orthocell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results